论文部分内容阅读
刚刚过去的2006年,是中国医药行业极不平静的一年,也是发生重大变化的一年,在中国医药发展过程中也是有影响力的一年。″齐二药″和″欣弗″事件人命关天;国家食品药品监督管理局高官相继落马;国家发改委大范围对药品再次降价;老百姓″就医难、看病难″的老问题依然困扰着整个社会,并引起广泛的关注和批评。竞争激烈的零售市场也同样狼烟四起,经过几年的残酷竞争,2006年零售市场进一步优胜劣汰,强势终端扩张速度加快,成为主流,并且开始向规范化管理迈进。可以说,2006年是中国药品零售市场发展的转折点。
The just-past 2006 was a very unmanageable year for China’s pharmaceutical industry and a year of major changes. It was also an influential year in the development of Chinese medicine. “Qi two drugs” and “Xin Fu” incident life close; the State Food and Drug Administration officials have been arrested; the National Development and Reform Commission a wide range of drugs again cut prices; people “medical treatment difficult to see a doctor,” the old problems still plagued the entire community , And aroused widespread concern and criticism. In the highly competitive retail market, the same fiery and vehemence have taken place. After several years of brutal competition, the retail market was further survival of the fittest in 2006 and the expansion of strong terminals accelerated. It became the mainstream and began to move toward standardized management. It can be said that 2006 is a turning point in the development of China’s pharmaceutical retail market.